KIM-1 as a potential serological/urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity

Cover Page

Cite item

Full Text

Abstract

The last decades are characterized by an active search for highly sensitive and specific urinological and serological tumor-associated markers of renal cell carcinoma. This review analyses the results of studies of traditional serological tumor-associated markers and a potential new tumor-associated marker of renal cell carcinoma: kidney injury molecule-1, or KIM-1. The structure, sources and functions of KIM-1 in normal conditions and in damaged renal tubules, its potential role in carcinogenesis are described. The experience of using KIM-1 for specifying diagnosis of the most common histological types of renal cell carcinoma is analyzed. Data on KIM-1 expression in malignant tumors in other locations and non-oncological kidney disorders are presented. The role of KIM-1 in early diagnosis of nephrotoxic effect of antitumor drugs is described. The accumulated data is promising in regards to using KIM-1 in clinical oncology as a urinological and serological marker of renal cell carcinoma and chemotherapy nephrotoxicity.

About the authors

M. P. Solokhina

National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: solomar59@mail.ru
ORCID iD: 0000-0003-0676-600X

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

N. S. Sergeeva

National Medical Research Radiological Center, Ministry of Health of Russia;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: prognoz.01@mail.ru
ORCID iD: 0000-0001-7406-9973

3 2nd Botkinskiy Proezd, Moscow 125284, 

1 Ostrovityanova St., Moscow 117997

Russian Federation

N. V. Marshutina

National Medical Research Radiological Center, Ministry of Health of Russia

Email: nin.mars@mail.ru
ORCID iD: 0000-0003-2997-4936

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

I. I. Alentov

National Medical Research Radiological Center, Ministry of Health of Russia

Email: igor@pushkino.tv
ORCID iD: 0000-0002-5920-5823

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

K. Yu. Kanukoev

National Medical Research Radiological Center, Ministry of Health of Russia

Email: kan12390@mail.ru

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

K. M. Nyushko

National Medical Research Radiological Center, Ministry of Health of Russia

Email: kirandja@yandex.ru
ORCID iD: 0000-0002-4171-6211

3 2nd Botkinskiy Proezd, Moscow 125284

B. Ya. Alekseev

National Medical Research Radiological Center, Ministry of Health of Russia

Email: byalekseev@mail.ru
ORCID iD: 0000-0002-1353-2271

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

A. D. Kaprin

National Medical Research Radiological Center, Ministry of Health of Russia

Email: kaprin@mail.ru
ORCID iD: 0000-0001-8784-8415

3 2nd Botkinskiy Proezd, Moscow 125284

References

  1. State of oncological care in Russia in 2017. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).
  2. Grankvist K., Ljungberg B., Rasmuson T. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer 1997;74(2):233–6. doi: 10.1002/(SICI)10970215(19970422)74:2<233::AIDIJC17>3.0.CO;2-E.
  3. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343–7. doi: 10.1097/00005392-20000100000092.
  4. Banyra O.B., Stroy A.A., Shulyak A.V. Tumor markers in kidney cancer diagnosing. Eksperimental’naya i klinicheskaya urologiya = Experimental and Clinical Urology 2011;4:72–8. (In Russ.).
  5. Hotakainen K., Ljungberg B., Paju A. et al. The free β-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 2002;86(2):185–9. doi: 10.1038/sj.bjc.6600050.
  6. Stenman U., Paju A., Jakobsen A. Prognostic significance of tumor-associated trypsin inhibitor in renal cell carcinoma. Libro de Abstracts. 2001;125.
  7. Zurita A.J., Jonasch E., Wang X. et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23(1):46–52. doi: 10.1093/annonc/mdr047.
  8. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312–8. doi: 10.1200/JCO.2008.19.5511.
  9. Sergeeva N.S., Rusakov I.G., Marshutina N.V. et al. Examination of a serological tumor marker Tu M2-PK in patients with renal carcinoma. Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2005;3:30–2. (In Russ.).
  10. Wechsel H.W., Petri E., Bichler K.H., Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999;19(4A):2583–90.
  11. Su Kim D., Choi Y.D., Moon M. et al. Composite Three-marker assay for early detection of kidney cancer. Cancer Epidemiol Biomarkers Prev 2013;22(3):390–8. doi: 10.1158/1055-9965.EPI-12-1156.
  12. Klyuchagina Yu.I., Sokolova Z.A., Baryshnikova M.A. Role of PD-1 receptor and its ligands PD-L1 and PD-L2 in cancer immunotherapy. Onkopediatriya = Oncopediatrics 2017;4(1):49–55. (In Russ.). doi: 10.15690/опоо.у4И.1684.
  13. Kushlinskiy N.E., Gershtein E.S., Morozov A.A. et al. Soluble ligand of the immune control point receptor (sPD-Ll) in serum in renal cell carcinoma. Byulleten’ eksperimental’noy biologii i meditsiny = Bulletin of experimental biology and medicine 2018; 166(9):325–9. (In Russ.).
  14. Zhang W., Ni M., Su Y. et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur Urol Focus 2018;4(3):412–9. doi: 10.1016/j.euf.2016.09.007.
  15. Scelo G., Muller D.C., Riboli E. et al. KIM1 as a blood-based marker for early detection of kidney cancer: a prospective nested casecontrol study. Clin Cancer Res 2018;24(22):5594–601. doi: 10.1158/10780432.CCR-18-1496.
  16. Han W.K., Alinani A., Wu C.L. et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005;16(4):1126–34. doi: 10.1681/ASN.2004070530.
  17. Bailly V., Zhang Z., Meier W. et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002;277(42):39739–48. doi: 10.1074/jbc.M200562200.
  18. Ichimura T., Bonventre J.V., Bailly V. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273(7):4135–42. doi: 10.1074/jbc.273.7.4135.
  19. Ismail O.Z., Zhang X., Bonventre J.V., Gunaratnam L. G protein α12 (Gα12) is a negative regulator of kidney injury molecule1-mediated efferocytosis. Am J Physiol Renal Physiol 2016;310(7):607–20. doi: 10.1152/ajprenal.00169.2015.
  20. Medić B., Rovcanin B., Vujovic K.S. et al. Evaluation of novel biomarkers of acute kidney injury: the possibilities and limitations. Curr Med Chem 2016;23(19):1981– 97. doi: 10.2174/092986732366616021013025.
  21. Yin C., Wang N. Kidney injury molecule-1 in kidney disease. Ren Fail 2016;38(10):1567– 73. doi: 10.1080/0886022X.2016.1193816.
  22. Tami C., Silberstein E., Manangeeswaran M. et al. Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR-1), and the association of IgA with HAVCR-1 enhances virus-receptor interactions. J Virol 2007;81(7):3437–46. doi: 10.1128/JVI.01585-06.
  23. Amin R.P., Vickers A.E., Sistare F. et al. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 2004;112(4):465–79. doi: 10.1289/ehp.6683.
  24. Lim A.I., Tang S.C., Lai K.N., Leung J.C. Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells? J Cell Physiol 2013;228(5):917–24. doi: 10.1002/jcp.24267.
  25. Ichimura T., Brooks C.R., Bonventre J.V. Kim-1/Tim-1 and immune cells: shifting sands. Kidney Int 2012;81(9):809–11. doi: 10.1038/ki.2012.11.
  26. Van Timmeren M.M., van den Heuvel M.C., Bailly V. et al. Tubular kidney injury molecule1 (KIM-1) in human renal disease. J Pathol 2007;212(2):209–17. doi: 10.1002/path.2175.
  27. Kramer A.B., van Timmeren M.M., Schuurs T.A. et al. Reduction of proteinuria in adriamycininduced nephropathy is associated with reduction of renal kidney injury molecule (Kim-1) over time. Am J Physiol Renal Physiol 2009;296(5):1136–45. doi: 10.1152/ajprenal.00541.2007.
  28. Kuehn E.W., Park K.M., Somlo S., Bonventre J.V. Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal Physiol 2002;283(6):1326–36. doi: 10.1152/ajprenal.00166.2002.
  29. Ichimura T., Asseldonk E.J., Humphreys B.D. et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118(5):1657–68. doi: 10.1172/JCI34487.
  30. Silberstein E., Dveksler G., Kaplan G.G. Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteinerich region of HAV cellular receptor-1. J Virol 2001;75(2):717–25. doi: 10.1128/JVI.75.2.717-725.2001.
  31. Rodriguez-Manzanet R., DeKruyff R., Kuchroo V.K., Umetsu D.T. The costimulatory role of TIM molecules. Immunol Rev 2009;229(1):259–70. doi: 10.1111/j.1600-065X.2009.00772.x.
  32. Meyers J.H., Sabatos C.A., Chakravarti S., Kuchroo V.K. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med 2005;11(8):362–9. doi: 10.1016/j.molmed.2005.06.008.
  33. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002;111(7):927–30. doi: 10.1016/S0092-8674(02)01201-1.
  34. Cohen H.T., Francis J., Mcgovern F.J. Renal-Cell Carcinoma. N Engl J Med 2005;353(23):2477–90. doi: 10.1056/NEJMra043172.
  35. Vilà M.R., Kaplan G.G., Feigelstock D. et al. Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int 2004;65(5):1761–73. doi: 10.1111/j.1523-1755.2004.00601.x.
  36. Kaplan G., Totsuka A., Thompson P. et al. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 1996;15(16):4282–96. doi: 10.1002/j.1460-2075.1996.tb00803.x.
  37. Cuadros T., Trilla E., Sarró E. et al. HAVCR/ KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. Cancer Res 2014;74(5):1416–28. doi: 10.1158/0008-5472.CAN-13-1671.
  38. Jung J.E., Lee H.G., Cho I.H. et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005;19(10):1296–8. doi: 10.1096/fj.043099fje.
  39. Martin T.A. The role of tight junctions in cancer metastasis. Semin Cell Dev Biol 2014;36:224–31. doi: 10.1016/j.semcdb.2014.09.008.
  40. Martin T.A., Harrison G.M., Mason M.D., Jiang W.G. HAVCR-1 reduces the integrity of human endothelial tight junctions. Anticancer Res 2011;31(2):467–73.
  41. Dong Y.C., Wu B., Wang J.D. et al. Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms. Zhonghua Bing Li Xue Za Zhi 2010;39(1):35–9.
  42. Mijuskovic M., Stanojevic I., Milovic N. et al. Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma. Int Urol Nephrol 2018;50(1):63–70. doi: 10.1007/s11255017-1724-6.
  43. Shalabi A., Abassi Z., Awad H. et al. Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell carcinoma. World J Urol 2013;31(6):1541–5. doi: 10.1007/s00345013-1043-1.
  44. Lin F., Zhang P.L., Yang X.J. et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 2007;31(3):371–81. doi: 10.1097/01.pas.0000213353.95508.67.
  45. Dent J., Hall G.D., Wilkinson N. et al. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridization. Br J Cancer 2003;88(10):1578–83. doi: 10.1038/sj.bjc.6600896.
  46. Sangoi A.R., McKenney J.K., Brooks J.D. et al. Evaluation of putative renal cell carcinoma markers PAX-2, PAX-8, and hKIM-1 in germ cell tumors: a tissue microarray study of 100 cases. Appl Immunohistochem Mol Morphol 2012;20(5):451–3. doi: 10.1097/PAI.0b013e31824bb404.
  47. Liu L., Song Z., Zhao Y. et al. HAVCR-1 expression might be a novel prognostic factor for gastric cancer. PLoS One 2018;13(11):0206423. doi: 10.1371/journal.pone.0206423.
  48. Telford E.J., Jiang W.G., Martin T.A. HAVCR-1 involvement in cancer progression. Histol Histopathol 2017;32(2):121–8. doi: 10.14670/HH-11-817.
  49. Wang Y., Martin T.A., Jiang W.G. HAVCR-1 expression in human colorectal cancer and its effects on colorectal cancer cells in vitro. Anticancer Res 2013;33(1):207–14.
  50. Seibert F.S., Sitz M., Passfall J. et al. Prognostic value of urinary calprotectin, NGAL and KIM-1 in chronic kidney disease. Kidney Blood Press Res 2018;43(4):1255–62. doi: 10.1159/000492407.
  51. Zhao X., Zhang Y., Li L. et al. Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. Am J Nephrol 2011;34(3):268–80. doi: 10.1159/000330187.
  52. De Carvalho J.A., Tatsch E., Hausen B.S. et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin Biochem 2016;49(3):232–6. doi: 10.1016/j.clinbiochem.2015.10.016.
  53. Waikar S.S., Sabbisetti V., Ärnlöv J. et al. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol Dial Transplant 2016;31(9):1460–70. doi: 10.1093/ndt/gfw203.
  54. Sun I.O., Santelli A., Abumoawad A. et al. Loss of renal peritubular capillaries in hypertensive patients is detectable by urinary endothelial microparticle levels. Hypertension 2018;72(5):1180–8. doi: 10.1161/HYPERTENSIONAHA.118.11766.
  55. Dallatu M.K., Nwokocha E., Agu N. et al. The role of hypoxia-inducible factor/prolyl hydroxylation pathway in deoxycorticosterone acetate/salt hypertension in the rat. J Hypertens (Los Angel) 2014;3(6). doi: 10.4172/2167-1095.1000184.
  56. Kandhare A.D., Patil M.V., Bodhankar S.L. L-Arginine attenuates the ethylene glycol induced urolithiasis in ininephrectomized hypertensive rats: role of KIM-1, NGAL, and NOs. Ren Fail 2015;37(4):709–21. doi: 10.3109/0886022X.2015.1011967.
  57. Lacquaniti A., Donato V., Pintaudi B. et al. “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol 2013;50(6):935–42. doi: 10.1007/s00592-013-0485-7.
  58. Humphreys B.D., Xu F., Sabbisetti V. et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013;123(9):4023–35. doi: 10.1172/JCI45361.
  59. Chawla L.S., Eggers P.W., Star R.A., Kimmel P.L. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014;371(1):58–66. doi: 10.1056/NEJMra1214243.
  60. Dubin R.F., Judd S., Scherzer R. et al. Urinary tubular injury biomarkers are associated with ESRD and death in the REGARDS study. Kidney Int Rep 2018;3(5):1183–92. doi: 10.1016/j.ekir.2018.05.013.
  61. Brovko M.Yu., Pulin A.A., Kustova T.Yu. et al. Significance of the determination of urinary excretion of kidney injury molecule-1 (KIM-1) in the assessment of the activity and prognosis of chronic glomerulonephritis. Terapevticheskiy arkhiv = Therapeutic Archive 2016;88(6):51–7. (In Russ.). doi: 10.17116/terarkh201688651-57.
  62. Lieberthal J.G., Cuthbertson D., Carette S. et al. Urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2013;40(5):674–83. doi: 10.3899/jrheum.120879.
  63. Xu P.C., Zhang J.J., Chen M. et al. Urinary kidney injury molecule-1 in patients with IgA nephropathy is closely associated with disease severity. Nephrol Dial Transplant 2011;26(10):3229–36. doi: 10.1093/ndt/gfr023.
  64. Fahmy N., Sener A., Sabbisetti V. et al. Urinary expression of novel tissue markers of kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J Endourol 2013;27(12):1455–62. doi: 10.1089/end.2013.0188.
  65. Urbschat A., Gauer S., Paulus P. et al. Serum and urinary NGAL but not KIM-1 raises in human postrenal AKI. Eur J Clin Invest 2014;44(7):652–9. doi: 10.1111/eci.12283.
  66. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin Nephrol 2003;23(5):460–4.
  67. Horie S., Oya M., Nangaku M. et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 2018;22(1):210–44. doi: 10.1007/s10157017-1448-z.
  68. Hostetter T.H., Olson J.L., Rennke H.G. et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001;12(6):1315–25. doi: 10.1152/ajprenal.1981.241.1.F85.
  69. Dieterle F., Sistare F., Goodsaid F. et al. Renal biomarker qualification submission: A dialog between the FDA–EMEA and predictive safety testing consortium. Nat Biotechnol 2010;28(5):455–62. doi: 10.1038/nbt.1625.
  70. Sahni V., Choudhury D., Ahmed Z. Chemotherapyassociated renal dysfunction. Nat Rev Nephrol 2009;5(8):450–62. doi: 10.1038/nrneph.2009.97.
  71. Mohamad M.A., Mohamad R.A., Fatemeh A., Mohamad R.S. Histological study of toxic effects of cisplatin single dose injection on rat kidney. Gene Cell Tissue 2014;1:21536. doi: 10.17795/gct-21536.
  72. Kokura K., Kuromi Y., Endo T. et al. A kidney injury molecule-1 (Kim-1) gene reporter in a mouse artificial chromosome: the responsiveness to cisplatin toxicity in immortalized mouse kidney S3 cells. J Gene Med 2016;18(10):273–81. doi: 10.1002/jgm.2925.
  73. Park E.J., Kwon H.K., Choi Y.M. et al. Doxorubicin induces cytotoxicity through upregulation of pERK-dependent ATF3. PLoS One 2012;7(9):44990. doi: 10.1371/journal.pone.0044990.
  74. Tekce B.K., Uyeturk U., Tekce H. et al. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann Clin Biochem 2015;52(Pt 1):88– 94. doi: 10.1177/0004563214528312.
  75. Shinke H., Masuda S., Togashi Y. et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 2015;76(5):989–96. doi: 10.1007/s00280-015-2880-y.
  76. Abdelsalam M., Elmorsy E., Abdelwahab H. et al. Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity. BMC Nephrol 2018;19(1):219. doi: 10.1186/s12882-018-1022-2.
  77. Carvalho Pedrosa D., Macedo de Oliveira Neves F., Cavalcante Meneses G. et al. Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study. Pediatr Nephrol 2015;30(12):2207–13. doi: 10.1007/s00467-015-3178-3.
  78. Sinha V., Vence L.M., Salahudeen A.K. Urinary tubular protein-based biomarkers in the rodent model of cisplatin nephrotoxicity: a comparative analysis of serum creatinine, renal histology, and urinary KIM-1, NGAL, and NAG in the initiation, maintenance, and recovery phases of acute kidney injury. J Investig Med 2013;61(3):564–8. doi: 10.2310/JIM.0b013e31828233a8.
  79. Pianta T.J., Succar L., Davidson T. et al. Monitoring treatment of acute kidney injury with damage biomarkers. Toxicol Lett 2017;268:63–70. doi: 10.1016/j.toxlet.2017.01.001.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36986 от  21.07.2009.